非曲霉霉菌所致侵袭性真菌感染的诊断与管理
本综述详细讨论毛霉目、赛多孢菌属(Scedosporium)、多育节荚孢霉(Lomentospora prolificans)和镰刀菌属,并总结宛氏拟青霉(Paecilomyces variotii)、淡紫紫孢菌(Purpureocillium lilacinum)和Rasamsonia属等新兴非曲霉霉菌的微生物学、危险因素、诊断与治疗。非曲霉霉菌感染诊断困难,分子方法日益重要。治疗需多管齐下、多学科协作,手术、纠正基础危险因素和增强宿主免疫应答与抗真菌治疗同等重要。许多非曲霉霉菌对现有获批抗真菌药固有耐药,治疗选择需依据药敏试验。新型抗真菌药在研发中,未来有望改善疗效与安全性。需持续研究以明确流行病学并开发更好的诊断工具和治疗方案。
要点
- 非曲霉霉菌感染因免疫抑制人群扩大而呈增加趋势。
- 许多非曲霉霉菌对现有获批抗真菌药固有耐药,治疗选择需依据药敏试验。
- 治疗采用多管齐下、多学科协作,手术、纠正危险因素和增强免疫与抗真菌治疗同等重要。
核心结论
- 非曲霉霉菌所致侵袭性真菌感染是显著致病和致死原因,其感染似在增加。
- 治疗需多管齐下、多学科协作,手术、纠正基础危险因素和增强宿主免疫应答与抗真菌治疗同等重要。
- 许多非曲霉霉菌对现有获批抗真菌药固有耐药,治疗选择需依据药敏试验。
- 新型抗真菌药在研发中,未来有潜力改善抗真菌治疗的疗效与安全性。
- 需持续研究以充分描述非曲霉霉菌感染的流行病学,并开发更好的诊断工具和治疗方案。
研究设计与样本
- 本综述详细讨论毛霉目、赛多孢菌属(Scedosporium)、多育节荚孢霉(Lomentospora prolificans)和镰刀菌属。
- 本综述总结宛氏拟青霉(Paecilomyces variotii)、淡紫紫孢菌(Purpureocillium lilacinum)和Rasamsonia属等新兴非曲霉霉菌的微生物学、危险因素、诊断与治疗。
主要发现
- 非曲霉霉菌感染因免疫抑制宿主人群不断扩大而似在增加。
- 诊断挑战被强调,分子方法的新兴重要性被讨论。
- 许多非曲霉霉菌对现有获批抗真菌药固有耐药。
- 新型抗真菌药在研发中,未来有潜力改善疗效与安全性。
临床怎么用
- 治疗非曲霉霉菌所致侵袭性真菌感染需采用多管齐下、多学科协作的方法。
- 手术、纠正基础危险因素和增强宿主免疫应答与抗真菌治疗同等重要。
- 抗真菌治疗选择需依据药敏试验指导。
局限性
- 需持续研究以充分描述非曲霉霉菌感染的流行病学,并开发更好的诊断工具和治疗方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Invasive fungal infection (IFI) due to moulds other than Aspergillus are a significant cause of morbidity and mortality. Non-Aspergillus mould (NAM) infections appear to be on the increase due to an ever-expanding population of immunocompromised hosts. In this review, Mucorales, Scedosporium species, Lomentospora prolificans and Fusarium species are examined in detail, and the microbiology, risk factors, diagnosis and treatment of emerging NAMs such as Paecilomyces variotti, Purpureocillium lilacinum and Rasamsonia are summarized. The challenges in diagnosis are emphasized and the emerging importance of molecular methods is discussed. Treatment of IFI due to NAMs is a multi-pronged and multi-disciplinary approach. Surgery, correction of underlying risk factors, and augmentation of the host immune response are as important as antifungal therapy. Many of these NAMs are intrinsically resistant to the currently licensed antifungal agents, so selection of therapy needs to be guided by susceptibility testing. There are new antifungal agents in development, and these have the potential to improve the efficacy and safety of antifungal treatment in the future. Ongoing research is required to fully delineate the epidemiology of NAM infections, and to develop better diagnostic tools and treatments so that outcomes from these infections can continue to improve.
引用
- Morrissey CO. Diagnosis and management of invasive fungal infections due to non-Aspergillus moulds. J Antimicrob Chemother. 2025. PMID: 40085540. doi:10.1093/jac/dkaf005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。